Fagron NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
12 apr 2016 - 07:00
Statutaire naam
Fagron NV
Titel
Fagron NV: Turnover from continued operations increased by 0.9% to € 103.6 million
Bericht
Regulated information
Waregem (Belgium)/Rotterdam (The Netherlands)[1], 12 April 2016
Turnover from continued operations increased by 0.9% to € 103.6 million
Fagron decides to close Bellevue Pharmacy
Fagron's consolidated turnover from continued operations increased by 0.9% (+7.2% at constant exchange rates) to € 103.6 million during the first quarter of 2016. Organic turnover growth from continued operations amounted to -6.0% (-0.1% at constant exchange rates).
After the change in the reimbursement system for non-sterile compounding in the United States in 2015, Bellevue Pharmacy (part of Fagron Specialty Pharma Services) became loss-making in the first quarter of 2016. The Board of Directors has therefore decided to close Bellevue Pharmacy. The production of non-sterile compounding at Bellevue Pharmacy was stopped in March 2016 and the majority of the employees have been made redundant. Due to this decision, the turnover of Bellevue Pharmacy is reported in this press release under discontinued operations.
Datum laatste update: 07 oktober 2024